The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JASPAC 06: Observational study of FOLFIRINOX therapy for unresectable and recurrent pancreatic cancer—Preliminary report on serious adverse events.
 
Masato Ozaka
No Relationships to Disclose
 
Akiko Todaka
Consulting or Advisory Role - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Keita Mori
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Lilly; Novartis; OncoTherapy Science; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Hideki Ueno
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Lilly (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Novartis
 
Kazuhiro Uesugi
No Relationships to Disclose
 
Noritoshi Kobayashi
No Relationships to Disclose
 
Hideyuki Hayashi
No Relationships to Disclose
 
Kentaro Sudo
No Relationships to Disclose
 
Naohiro Okano
Honoraria - Yakult Honsha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Yosuke Horita
No Relationships to Disclose
 
Keiko Kamei
No Relationships to Disclose
 
Seigo Yukisawa
No Relationships to Disclose
 
Shoji Nakamori
No Relationships to Disclose
 
Yutaka Yachi
Employment - Daiichi Sankyo
 
Toshiyuki Henmi
Employment - Yakult Honsha
 
Marina Kobayashi
No Relationships to Disclose
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Yakult Honsha (Inst)